Role of SphK/S1P in cardiovascular diseases

doi:10.16352/j.issn.1001-6325.2024.08.1175

Abstract

Abstract: Sphingosine-1-phosphate (S1P) is a highly active membrane phospholipid metabolite with important physiological roles in the cardiovascular system. Sphingosine kinase (SphK) is a lipase that is important for maintaining stable S1P levels in vivo. S1P exerts different physiological effects in cardiovascular diseases by catalytically regulating the binding of S1P to G protein-coupled receptors (S1PR1-5) on the cell surface, thus exerting different physiological effects in cardiovascular diseases.For example, they are involved in regulating the development of diseases such as atherosclerosis, myocardial ischemia-reperfusion injury, myocardial infarction, heart failure and other diseases, maintaining the barrier function of vascular endothelial cells, protecting the endothelial glycocalyx layer, leukocyte adhesion, inflammatory reactions and other pathophysiologic processes.

Key words: sphingosine-1-phosphate, sphingosine kinase, cardiovascular diseases, endothelial glycocalyx layer

CLC Number:

TANG Lihong, CHEN Chunling. Role of SphK/S1P in cardiovascular diseases[J]. Basic & Clinical Medicine, 2024, 44(8): 1175-1179.

References

[1] Dixit D, Hallisey VM, Zhu EY, et al. S1PR1 inhibition induces proapoptotic signaling in T cells and limits humoral responses within lymph nodes[J]. J Clin Invest, 2024,134:e174984. doi:10.1172/JCI174984.
[2] Zhao T, Ding T, Sun Z, et al. SPHK1/S1P/S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial-mesenchymal transition[J]. FASEB J, 2024,38:e23417. doi:10.1096/fj.202301323R.
[3] Li JJ, Zhao XY, Wang Y, et al. Endothelial KCa3.1 and KCa2.3 mediate S1P(sphingosine-1-phosphate)-depend-ent vasodilation and blood pressure homeostasis[J]. Arterioscler Thromb Vasc Biol, 2023,43:726-738. doi:10.1161/ATVBAHA.122.318820.
[4] Ji X, Chen Z, Wang Q, et al. Sphingolipid metabolism controls mammalian heart regeneration[J]. Cell Metab, 2024,36:839-856.e8.
[5] Karam M, Auclair C. Sphingosine-1-phosphate as lung and cardiac vasculature protecting agent in SARS-CoV-2 infection[J]. Int J Mol Sci, 2023,2413088. doi:10.3390/ijms241713088.
[6] Therond P, Chapman MJ. Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment[J]. Curr Opin Lipidol, 2022,33:199-207. doi:10.1097/MOL.0000000000000825.
[7] Sawashita Y, Kazuma S, Tokinaga Y, et al. Albumin protects the ultrastructure of the endothelial glycocalyx of coronary arteries in myocardial ischemia-reperfusion injury in vivo[J]. Biochem Biophys Res Commun, 2023,666:29-35. doi:10.1016/j.bbrc.2023.04.110.
[8] Piccoli M, Cirillo F, Ghiroldi A, et al. Sphingolipids and atherosclerosis: the dual role of ceramide and sphingosine-1-phosphate[J]. Antioxidants (Basel), 2023,12:143. doi:10.3390/antiox12010143.
[9] Yu FC, Yuan CX, Tong JY, et al. Protective effect of sphingosine-1-phosphate for chronic intermittent hypoxia-induced endothelial cell injury[J]. Biochem Biophys Res Commun, 2018,498:1016-1021. doi:10.1016/j.bbrc.2018.03.106.
[10] Katunaric B, SenthilKumar G, Schulz ME, et al. S1P(sphingosine-1-phosphate)-induced vasodilation in human resistance arterioles during health and disease[J]. Hypertension, 2022,79:2250-2261. doi:10.1161/HYPERTENSIONAHA.122.19862.
[11] Manzo OL, Nour J, Sasset L, et al. Rewiring endothelial sphingolipid metabolism to favor S1P over ceramide protects from coronary atherosclerosis[J]. Circ Res, 2024,134:990-1005. doi:10.1161/CIRCRESAHA.123.323826.
[12] Liu X, Wu J, Zhu C, et al. Endothelial S1pr1 regulates pressure overload-induced cardiac remodelling through AKT-eNOS pathway[J]. J Cell Mol Med,2020,24:2013-2026. doi:10.1111/jcmm.14900.
[13] 陈铿铨,王忠芹,刘超等.1-磷酸鞘胺醇通过其受体3改善压力超负荷诱导的病理性心肌肥厚[J].中国心血管杂志,2022,27:459-467.
[14] Magaye RR, Savira F, Hua Y, et al. Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells[J]. Int J Biochem Cell Biol, 2021,134:105952. doi:10.1016/j.biocel.2021.105952.
[15] 贺洵莹,杜雄兵.血浆1-磷酸神经鞘氨醇和鞘磷脂在缺血性心肌病收缩性心力衰竭的预测价值[J].广东医学,2018,39:3487-3490.doi:10.13820/j.cnki.gdyx.20181221.011.
[16] Mihanfar A, Nejabati HR, Fattahi A, et al. The role of sphingosine 1 phosphate in coronary artery disease and ischemia reperfusion injury[J]. J Cell Physiol, 2019,234:2083-2094. doi:10.1002/jcp.27353.
[17] Wu X, Reboll MR, Korf-Klingebiel M, et al. Angiogen-esis after acute myocardial infarction[J]. Cardiovasc Res, 2021,117:1257-1273. doi:10.1093/cvr/cvaa287.
[18] Polzin A, Dannenberg L, Benkhoff M, et al. Sphingosine-1-phosphate improves outcome of no-reflow acute myocardial infarction via sphingosine-1-phosphate receptor 1[J]. ESC Heart Fail,2023,10:334-341. doi:10.1002/ehf2.14176.
[19] Fang R, Zhang LL, Zhang LZ, et al. Sphingosine 1-phosphate postconditioning protects against myocardial ischemia/reperfusion injury in rats via mitochondrial signaling and Akt-Gsk3β phosphorylation[J]. Arch Med Res,2017,48:147-155. doi:10.1016/j.arcmed.2017.03.013.
[20] Cong D, Yu Y, Meng Y, et al. Dexmedetomidine (Dex) exerts protective effects on rat neuronal cells injured by cerebral ischemia/reperfusion via regulating the Sphk1/S1P signaling pathway[J]. J Stroke Cerebrovasc Dis, 2023,32:106896. doi:10.1016/j.jstrokecerebrovasdis.2022.106896.
[21] Devarakonda T, Valle Raleigh J, Mauro AG, et al. Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling[J]. Sci Rep, 2022,12:8897. doi:10.1038/s41598-022-12930-x.